High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data

J Travel Med. 2021 Oct 11;28(7):taab090. doi: 10.1093/jtm/taab090.

¹ Department of Pharmacy, Sendai City Medical Center, Sendai, Miyagi, Japan.
² Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan.
³ Medical Governance Research Institute, Tokyo 108-0074, Japan.
⁴ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan.
⁵ Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal.
⁶ Internal Medicine, Navitas Clinic Kawasaki, Kanagawa 210-0007, Japan.

No abstract available

Keywords: BNT162b2 mRNA Covid-19 Vaccine; Japan; anaphylaxis; safety.

Publication types